Moreover, we also observed concurrent mutations of EGFR L858R and ERBB2 S310F in two adenocarcinoma patients; EGFR L858R and ERBB2 amplification in three LUAD patients (Table S3). This evidence concerns the gene ERBB2 and adenocarcinoma.